Loss of BRCA1 expression leads to worse survival in patients with gastric carcinoma

Table 1 Association between expression loss of homologous recombination markers and clinicopathological parameters in gastric cancer patients n (%)

	BRCA1 expression (n = 112)		ATM expression (n = 114)		ATR expression (n = 86)		MDC1 expression (n = 117)		Mre11 expression (n = 86)
	BRCA1-negative/total cases	P value	ATM-negative/total cases	P value	ATR-negative/total cases	P value	MDC1-negative/total cases	P value	Mre11-negative/total cases	P value
Age, yr (median)
< 61.3	15 (25.0)	0.043	9 (16.1)	0.133	8 (19.5)	0.193	8 (14.3)	0.625	2 (4.9)	0.119
≥ 61.3	9 (17.3)		14 (24.1)		10 (22.2)		5 (8.2)		2 (4.4)
Gender
Male	15 (19.7)	0.284	15 (19.5)	0.715	12 (21.1)	0.969	10 (12.7)	0.430	3 (5.0)	0.333
Female	9 (25.0)		8 (21.6)		6 (20.7)		3 (7.9)		1 (3.4)
Lauren type
Intestinal	4 (8.2)	0.001	12 (24.0)	0.846	8 (21.6)	0.891	0 (0.0)	0.001	2 (5.0)	0.303
Diffused	20 (31.7)		11 (17.2)		10 (20.4)		13 (19.7)		2 (4.3)
Tumor grade
I/II	3 (10.7)	0.047	7 (24.1)	0.513	5 (29.4)	0.327	0 (0.0)	0.012	1 (4.2)	0.742
III	15 (20.5)		15 (20.5)		10 (16.7)		9 (12.0)		3 (5.8)
IV	6 (54.5)		1 (8.3)		3 (33.3)		4 (30.8)		0 (0.0)
Clinical stage
I/II	4 (12.9)	0.006	6 (19.4)	0.560	6 (23.1)	0.593	3 (9.4)	0.092	2 (7.7)	0.562
III	10 (16.9)		11 (17.7)		7 (16.7)		5 (7.7)		2 (4.2)
IV	10 (45.5)		6 (28.6)		5 (27.8)		5 (25.0)		0 (0.0)

BRCA1: Breast cancer type 1 susceptibility protein; ATM: Ataxia telangiectasia mutated; ATR: ATM-Rad3-related; MDC1: Mediator of DNA damage checkpoint protein 1; Mre11: Meiotic recombination 11.